Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs

被引:18
|
作者
Chapman, RW [1 ]
House, A [1 ]
Liu, F [1 ]
Celly, C [1 ]
Mei, H [1 ]
Hey, JA [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
cough; tachykinin NK1 receptor; CP-99994; (dog);
D O I
10.1016/j.ejphar.2003.11.048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CP-99994 [(+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine] is a selective tachykinin NK1 receptor antagonist that inhibits cough in guinea pigs and cats. This study examined the antitussive effects of CP-99994 in dogs produced by mechanical stimulation of the intrathoracic trachea. CP-99994 (10 mg/kg, p.o.) inhibited cough frequency by 52% at 2 h, 31% at 6 h and by 21% at 24 h. Cough amplitude was inhibited by 45% at 6 h but unchanged at 2 and 24 h after CP-99994. Plasma levels of CP-99994 were highest at 2 h (75 +/- 26 ng/ml) and fell to 22 +/- 6 ng/ml at 6 h. These results demonstrate antitussive activity of CP-99994 in dogs at a dose proven to antagonize tachykinin NK1 receptors in this species. (C) 2003 Elsevier B.V All rights reserved.
引用
收藏
页码:329 / 332
页数:4
相关论文
共 50 条
  • [31] The human tachykinin, NK1 (short form) and tachykinin NK4 receptor:: a reappraisal
    Page, NM
    Bell, NJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 437 (1-2) : 27 - 30
  • [32] The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system
    Polley, JS
    Gaskin, PJ
    Perren, MJ
    Connor, HE
    Ward, P
    Beattie, DT
    REGULATORY PEPTIDES, 1997, 68 (01) : 23 - 29
  • [33] INVESTIGATION INTO SPECIES VARIANTS IN TACHYKININ NK1 RECEPTORS BY USE OF THE NONPEPTIDE ANTAGONIST, CP-96,345
    BERESFORD, IJM
    BIRCH, PJ
    HAGAN, RM
    IRELAND, SJ
    BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (02) : 292 - 293
  • [35] SCH 206272:: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist
    Anthes, JC
    Chapman, RW
    Richard, C
    Eckel, S
    Corboz, M
    Hey, JA
    Fernandez, X
    Greenfeder, S
    McLeod, R
    Sehring, S
    Rizzo, C
    Crawley, Y
    Shih, NY
    Piwinski, J
    Reichard, G
    Ting, P
    Carruthers, N
    Cuss, FM
    Billah, M
    Kreutner, W
    Egan, RW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (02) : 191 - 202
  • [36] Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor:: evidence from quantitation of receptor endocytosis
    Jenkinson, KM
    Southwell, BR
    Furness, JB
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) : 131 - 136
  • [37] Characterization of CP-122,721; A nonpeptide antagonist of the neurokinin NK1 receptor
    McLean, S
    Ganong, A
    Seymour, PA
    Bryce, DK
    Crawford, RT
    Morrone, J
    Reynolds, LS
    Schmidt, AW
    Zorn, S
    Watson, J
    Fossa, A
    DePasquale, M
    Rosen, T
    Nagahisa, A
    Tsuchiya, M
    Heym, J
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 277 (02): : 900 - 908
  • [38] In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK1 and NK2 receptor antagonist
    Robineau, P
    Lonchampt, M
    Kucharczyk, N
    Krause, JE
    Regoli, D
    Fauchere, JL
    Prost, JF
    Canet, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (2-3) : 677 - 684
  • [39] Gut feelings about tachykinin NK1 receptor antagonists
    Laird, J
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) : 169 - 169
  • [40] Polymorphic behavior of an NK1 receptor antagonist
    Wang, Y
    Wenslow, RM
    McCauley, JA
    Crocker, LS
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) : 147 - 159